BioWorld tracked 260 clinical trial readouts across phases I through III in June 2026, compared to 262 in May. By phase, BioWorld recorded 87 phase I readouts in May, 90 in phase II and 83 in phase III, a relatively even spread across phases. Of the phase III programs, 32 trials posted positive results, and five failed to meet primary endpoints.

Med-tech deal value, covering licensing agreements, joint ventures and development collaborations, through the first half (H1) of 2026 reached $5.28 billion, the second-highest H1 total behind 2023’s $6.88 billion.

Biopharma deal value through the first half (H1) of 2026 totaled $170.11 billion, the highest H1 total in BioWorld’s records by a wide margin and a 22% increase from H1 2025’s $139.35 billion, the previous record high. Both quarters were strong, with the first quarter (Q1) contributing $79.71 billion and Q2 jumping to $90.4 billion, the highest single quarter on record after edging past Q4 2024’s $80.65 billion.

Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to international partnerships, licensing, clinical development and a bigger role in the global biomedical ecosystem.

Global drug approvals through the first half (H1) of 2026 reached 261, the third-highest H1 total in BioWorld’s records behind 2021’s 288 and 2025's 271, and ahead of 2022’s 256. June was the standout month of the first six months at 64 approvals, the highest single month in BioWorld’s records and a notable acceleration from May’s 43.